Image pharmaphorum Editor Views & Analysis What CX Tech Innovations Options Are Ripe for Consideration? Innovation is often driven by frustration. Views & Analysis Life sciences must become cloud-first to seize the science o... If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufa Views & Analysis Why pharma isn’t yet achieving digital excellence, and how i... Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. Views & Analysis LEO Pharma’s new R&D lead on driving agility in drug develop... After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development. Load more results
Views & Analysis What CX Tech Innovations Options Are Ripe for Consideration? Innovation is often driven by frustration.
Views & Analysis Life sciences must become cloud-first to seize the science o... If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufa
Views & Analysis Why pharma isn’t yet achieving digital excellence, and how i... Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods.
Views & Analysis LEO Pharma’s new R&D lead on driving agility in drug develop... After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research and development.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.